161833-42-7

Basic information

• Product Name: 3-AMino-4-broMo-thiophene-2-carboxylicacidMethylester
• Synonyms: 3-AMino-4-broMo-thiophene-2-carboxylicacidMethylester;3-Amino-4-bromo-2-thiophenecarboxylic acid methyl ester
• CAS NO: 161833-42-7
• Molecular Formula: C₆H₆BrNO₂S
• Molecular Weight: 236.08634
• Mol File: 161833-42-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 333.6±37.0 °C(Predicted)
• Appearance: /
• Density: 1.745±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: -0.20±0.10(Predicted)
• CAS DataBase Reference: 3-AMino-4-broMo-thiophene-2-carboxylicacidMethylester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMino-4-broMo-thiophene-2-carboxylicacidMethylester(161833-42-7)
• EPA Substance Registry System: 3-AMino-4-broMo-thiophene-2-carboxylicacidMethylester(161833-42-7)

Safety Data

• Hazardous Substances Data: 161833-42-7(Hazardous Substances Data)

Usage

General Description

3-Amino-4-bromo-thiophene-2-carboxylic acid methyl ester is a chemical compound with a molecular formula C7H7BrNO2S. It is a methyl ester derivative of 3-amino-4-bromo-thiophene-2-carboxylic acid, which is used in the synthesis of various pharmaceuticals and organic compounds. 3-AMino-4-broMo-thiophene-2-carboxylicacidMethylester is a white to off-white solid that is soluble in organic solvents. It has potential applications in the pharmaceutical industry as a building block in the development of new drugs and therapeutic agents. It is also used in research and development laboratories for various purposes, including the synthesis of heterocyclic compounds and as a reagent in organic chemistry reactions. Overall, 3-Amino-4-bromo-thiophene-2-carboxylic acid methyl ester is a versatile compound with a range of potential applications in pharmaceuticals and chemical synthesis.

Upstream product

• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 

Downstream Products

• 215927-34-7 3-amino-4-bromothiophene-2-carboxylic acid 
• 632356-41-3 methyl 3-amino-4-chlorothiophene-2-carboxylate 
• 82437-65-8 methyl 3-amino-4-(4-methoxyphenyl)-2-thiophenecarboxylate 

Relevant articles and documents

THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA

The present description relates'to compounds of formula (I) useful for improving pre-mRNA splicing in a cell. In particular, another aspect of the present description relates to substituted thieno[3,2-b]pyridine compounds, forms, and pharmaceutical compos

Design, Synthesis, and SAR Studies of Heteroarylpyrimidines and Heteroaryltriazines as CB2R Ligands

Herein we describe the design and synthesis of a new series of heteroarylpyrimidine/heteroaryltriazine derivatives on the basis of quinazoline-2,4(1H,3H)-diones as CB2R-selective ligands using a bioisosterism strategy. An acetamide group was explored to displace the enamine linker of the lead compound for the purpose of stereoisomerism elimination and hydrophilicity increase. As a result, some of the synthesized compounds showed high bioactivity and selectivity for CB2R in calcium mobilization assays, and four displayed CB2R agonist activity, with EC50 values below 30 nm. The compound exhibiting the highest agonist activity toward CB2R (EC50=7.53±3.15 nm) had a selectivity over CB1R of more than 1328-fold. Moreover, structure–activity relationship (SAR) studies indicated that the substituents on the nucleus play key roles in the functionality of a ligand, with one such example demonstrating CB2R antagonist activity. Additionally, molecular docking simulations were conducted with the aim of better understanding of these new derivatives in relation to the structural requirements for agonists/antagonists binding to CB2R.

Heteroarylpyrimindinedione derivative and use thereof

The invention provides a heteroarylpyrimindinedione derivative and use thereof. The heteroarylpyrimindinedione derivative comprises a compound with a structure shown as general formula I, and a pharmaceutically acceptable salt or hydrate thereof. The derivative is obtained by chemical synthesis, and pharmacological experiments prove that the active ligand with cannabinoid type II receptor CB2 can be used for preparation of drugs for prevention and mitigation of CB2 receptor-mediated diseases, and the drug is cannabinoid CB2 receptor agonist's agonist, partial agonist, inverse agonist or antagonist. And the general structural formula I is shown as the specification.